Skip to main content
. 2021 Jun 1;5(6):e580. doi: 10.1097/HS9.0000000000000580

Table 1.

Different Types of Transplantation Platforms, Clinical Outcomes, Viral, Infections and Immune Repertoires.

Study Patients Donor Intervention Numbers (n) Acute GVHD Chronic GVHD EFS/OS CRFS Relapse NRM CMV EBV BK Adeno
ATG
 Chang et at14 Adult hematological malignancies MRD; PBSC/BM ATG-T 1.5 mg/kg on day –3 to –1 263 II–IV: 13.7% 2 y 27.9% (ext 8.5%) 3 y OS 69% 3 y 38.7% 3 y 20.8% 3 y 9.9% Day 100: 22.7% Day 180: 7.8% NA NA
III–IV: 8.4% LFS 65.7%
 Walker et al15 Adult hematological malignancies MUD/MMUD; PBSC/BM ATG-T 5 mg/kg on day –2, and 2 mg/kg on days –1 and +1 101 NA 2 y 26.3% 2 y OS 70.6% 1 y 57.6% 2 y 16.7% 2 y 21.2% NA 20% DNAemia requiring therapy NA NA
 Socié et al16 Adult hematological malignancies MUD; BM/PBSC ATG-F 20 mg/kg day –3 to –1 103 NA 3 y 12.2% 3 y OS 55% NA 3 y 33% 3 y 19% NA NA NA NA
 Baron et al17 Adult AML MRD/MUD; PBSC ATG-F 30 mg/kg or ATG-T 5 mg/kg; days not known 569 ATG-fresenius; 249 ATG-thymoglobulin II–IV: 18%–24% 2 y 30% 2 y 2 y 50%–52% 2 y 24%–28% 2 y NA NA NA NA
III–IV: 6%–7%; OS 67%–68% 11.5%–16%
LFS 60%–61%
 Finke et al18 Adult hematological malignancies MRD/MUD; PBSC/BM ATG-F 20 mg/kg on day –3 to –1 103 I–IV: 56.3% 2 y 30.8% (ext 12.2%) 2 y NA 2 y 28.9% 2 y 19.6% 53.8% DNAemia; 5.7% CMV disease 5% PTLD NA NA
II–IV: 33% OS 59.2%
III–IV: 11.7% EFS 51.6%
 Soiffer et al19 Adult AML, MDS, ALL MUD; PBSC/BM ATG-F 20 mg/kg –3 to –1 126 II–IV: 23% 2 y 16% 2 y 2 y 38% 2 y 32% 2 y 21% 62% (R+) DNAemia 1.6% PTLD NA NA
III–IV: 4.3% Moderate-severe 12% OS 59%
PFS 47%
Alemtuzumab
 Green et al20 Adult hematological malignancies Matched/mismatched; PBSC/BM Alemtuzumab dose 50–100 m 313 II–IV: 32%–40% 2 y 32%–41% NA NA 2 y 24%–36% 2 y 16%–24% >80% (R+) DNAemia NA NA NA
III–IV: 2%–15%
 van Besien et al21 Adult AML/MDS MRD/MUD/MMUD PBSC/BM Alemtuzumab 95 II–IV: 23.3% 2 y 16% 2 y NA 1 y 23.7% 1 y 24.6% NA NA NA NA
OS 40.5%
III–IV: 8.6% PFS 33%
 Carpenter et al22 Adult hematological malignancies MRD/MMRD/MUD/MMUD; PBSC/BM Alemtuzumab (75 in vivo, 36 ex vivo) 111 NA NA NA NA NA NA NA 2 y NA NA
40.3% DNAemia; 1% PTLD
PTCy
 Kanakry et al23 Adult leukemia/MDS MRD/MUD; BM PTCy 209 II–IV: 45% 3 y 13% 3 y OS 58% 3 y 39% 3 y 36% 3 y 17% NA NA NA NA
III–IV: 11% EFS 46%
 Cieri et al24 Adult high-risk hematological malignancy Haplo; PBSC PTCy 40 II–IV: 15% 1 y 20%; severe 5.1% 1 y OS 56% NA 1 y 35% 1 y 17% 63% DNAemia 15% DNAemia (66% of these pts treated). No PTLD 18% NA
III–IV: 7.5% EFS 48% 17% CMV disease
 Berger et al25 Pediatric; high-risk hematological malignancy Haplo; BM/PBSC PTCy 33 II–IV: 22% 1 y 4% 1 y OS 72% NA 1 y 24% 1 y 9% 36% DNAemia 3% DNAemia 17% 3% DNAemia; not symptomatic
III–IV: 3% EFS 61% No CMV disease No PTLD
 Devillier et al26 AML/high-risk MDS Haplo; BM/PBSC PTCy 60 II–IV: 18% 2 y 14%; severe 4% 1 y 1 y 37% 1 y 34% 1 y 27% NA NA NA NA
OS 50%
III–IV: 2% EFS 39%
 Mehta et al27 Adult hematological malignancies MMUD; BM/PBSC PTCy 41 II–IV: 37% 2 y 30% 2 y OS 52% NA 2 y 20% 2 y 35% NA NA NA NA
III–IV: 17% EFS 42%
 Mielcarek et al28 Adult hematological malignancies MRD/MUD/MMUD; PBSC PTCy 43 II–IV: 77% 1 y 16% requiring IS; ext 30% 2 y OS 70% 2 y 50% 2 y 17% 2 y 14% NA NA NA NA
III–IV: 0% 2 y EFS 69%
PTCy vs ATG
 Battipaglia et al29 Adult AML MMUD; BM/PBSC PTCy vs ATG-F/ATG-T 93 PTCY, 179 ATG PTCY PTCY PTCY PTCY: PTCY: PTCY: NA NA NA NA
II–IV: 30% Any: 39% 2 y OS: 56% 2 y 37% 2 y 29% 2 y 16%
III–IV: 9% Ext: 17% 2 y EFS: 55% ATG: ATG: ATG:
ATG: ATG ATG 2 y 28% 2 y 37% 2 y 29%
II–IV: 32% Any: 36% 2 y OS: 38%
III–IV: 19% Ext: 20% 2 y EFS: 34%
 Battipaglia et al30 Adult AML MRD; BM/PBSC PTCy vs ATG-F (26%)/ATG-T (74%) 197 PTCY, 1913 ATG PTCY PTCY PTCY PTCY: PTCY: PTCY: NA NA NA NA
II–IV: 19% Any: 37% 2 y OS: 64% 2 y 44% 2 y 36% 2 y 8%
III–IV: 6% Ext: 16% 2 y PFS: 55% ATG: ATG: ATG:
ATG: ATG ATG 2 y 49% 2 y 32% 2 y 10%
II–IV: 17% Any: 30% 2 y OS: 65%
III–IV: 6% Ext: 12% 2 y PFS: 58%
 Brissot et al31 Adult AML MUD; BM/PBSC PTCy vs ATG-T 5 mg/kg 174 PTCY, 1452 ATG PTCY PTCY PTCY PTCY: PTCY: PTCY: NA NA NA NA
II–IV: 28.8% Any: 31.4% 2 y OS: 62.7% 2 y 41.6% 2 y 25.2% 2 y 15.2%
III–IV: 8.8%; Ext: 18.5% 2 y PFS: 59.7% ATG: ATG: ATG:
ATG: ATG ATG 2 y 49.3% 2 y 23.7% 2 y 16.7%
II–IV: 29.2% Any: 33.6% 2 y OS: 64.8%
III–IV: 9% Ext: 13.1% 2 y PFS: 59.6%
 Ruggeri et al32 Adult AML MUD; BM/PBSC PTCy vs ATG-F/ATG-T 193 PTCY, 115 ATG PTCY PTCY PTCY PTCY: PTCY: PTCY: NA NA NA NA
III–IV: 4.7% Any: 33.7% 2 y OS: 58% 2 y 50.9% 2 y 21.6% 2 y 22.4%
ATG: Ext: 8.6% 2 y PFS: 56% ATG: ATG: ATG:
III–IV: 12.5% ATG ATG 2 y 38.9% 2 y 22.3% 2 y 30.5%
Any: 28.3% 2 y OS: 54.2%
Ext: 12.6% 2 y PFS: 47.2%
 Retière et al33 Adult hematological malignancies MRD/MUD/MMUD/haplo; BM/PBSC PTCy vs ATG-T 2.5 mg/kg on day –1 or days –2 and –1 30 PTCY, 15 ATG PTCY NA PTCY NA PTCY: NA DNAemia DNAemia requiring treatment PTCY 3% PTCY 15%
II–IV: 47% 2 y OS: 79% 2 y 17% PTCY 27% PTCY 0% ATG 0% ATG 20%
III–IV: 10% 2 y PFS: 63% ATG: ATG 40% ATG 33%
ATG: ATG 2 y 33%
II–IV: 47% 2 y OS: 73%
III–IV: 20% 2 y PFS: 60%
Ex vivo graft engineering
 Pasquini et al34 Adult AML MRD; PBSC CD34+ T cell depletion 44 II–IV: 23% 2 y 19% 2 y OS 59% 2 y 42% 2 y 24% 2 y 21% NA NA NA NA
III–IV: 4.5% EFS 55%
 Barba et al35 Adult leukemia MRD/MUD/MMUD; PBSC CD34+ T cell depletion 241 II–IV: 16% 3 y 5% 3 y OS 57% 1 y 65% 3 y 22% 3 y 24% NA NA NA NA
III–IV: 5% EFS 54% 3 y 52%
 Bayraktar et al36 Adult AML MRD/MUD/MMUD; PBSC/BM CD34+ T cell depletion 115 II–IV: 5% 3 y 13% 1 y OS 68% NA 1 y 17% 1 y 18% NA NA NA NA
III–IV: 1% EFS 62% 3 y 18% 3 y 24%
3 y OS 57%
EFS 58%
 van Esser et al37 Adult hematological malignancies SIB/MUD; BM/PBSC CD34+ T cell depletion or sheep erythrocyte rosetting 85 II–IV: 57% 1 y 38% NA NA NA 1 y 29% NA 54% (R+) DNAemia NA NA
12% PTLD
 de Witte et al38 Adult hematological malignancies MRD/MUD/MMUD; PBSC αβT cell depletion 35 II–IV: 37% 2 y 2 y NA 2 y 29% 2 y 32% 64% (R+) DNAemia, CMV disease 6% 44% NA NA
III–IV: 17% 23% OS 52%
Moderate: 17% EFS 40%
 Locatelli et al39 Pediatric AML/ALL Haplo; PBSC αβT cell/CD19 depletion 80 I–II skin only: 30% 0% 5 y: NA 5 y 24% 5 y 5% NA NA NA NA
>II or visceral: 0% OS 72%
LFS 71%
 Laberko et al40 pediatric malignant (114) + nonmalignant (68) MUD/haplo; PBSC αβT cell/CD19 depletion 182 Malignant: II–IV: 40% NA 2 y OS 68% NA 2 y 37% 2 y 13% 51% 33% NA NA
Nonmalignant II–IV: 27% 2 y malignant 58%
2 y nonmalignant 78%
 Lang et al41 Pediatric AML/MDS/nonmalignant Haplo; PBSC αβT cell/CD19 depletion 41 II: 10% 1.6 y average FU: 18% limited; 9% ext 1.6 y average FU: OS 52%; EFS NA NA 1.6 y average FU: 42% 1.6 y average FU: 7% NA NA NA NA
III–IV: 15%
 Maschan et al42 Pediatric high-risk AML MUD/MMUD/haplo; PBSC αβT cell/CD19 depletion 33 II: 23% 2 y 30% 2 y NA 2 y 31% 2 y 10% 52% DNAemia; 6% CMV disease 50% DNAemia; 6% rituximab NA NA
III: 16% OS 67%
IV: 0% EFS 60%
 Bertaina et al43 Pediatric nonmalignant Haplo; PBSC αβT cell/CD19 depletion 23 I–II: 13.1% 0% 2 y NA NA 9.3% 38% DNAemia CMV/adeno 50% DNAemia; 6% rituximab NA 38% DNAemia CMV/adeno
III–IV: 0% OS 91%
EFS 74%
 Balashov et al44 Pediatric nonmalignant MUD/MMRD/haplo; PBSC αβT cell/CD19 depletion 37 II: 21.5% Any 3% 2 y NA NA NA NA NA NA NA
IV: 2.8% Ext 3% OS 96.7%
EFS 67.7%

Depicted is a selection of studies.

Adeno = adenovirus; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; ATG = anti-thymocyte globulin; ATG-F = anti-thymocyte globulin-fresenius; ATG-T = anti-thymocyte globulin-thymoglobulin; BK = BK virus; BM = bone marrow; CMV = cytomegalovirus; CRFS = cGVHD-free relapse-free survival; cGVHD = chronic graft vs host disease; EBV = Epstein-Barr virus; EFS = event-free survival; ext = extensive; FU = follow up; GVHD = graft vs host disease; haplo = haploidentical donor; IS = immune suppression; LFS = leukemia-free survival; MDS = myelodysplastic syndrome; MMRD = mismatched related donor; MMUD = mismatched unrelated donor; MRD = matched related donor; MUD = matched unrelated donor; NA = not available; NRM = nonrelapse mortality; OS = overall survival; PBSC = peripheral blood stem cell; PFS = progression-free survival; PTCY = post-transplantation cyclophosphamide; PTLD = posttransplant lymphoproliferative disease; pts = patients; R+ = cytomegalovirus positive recipient; SIB = sibling; y = year.